NEW

Stryker Launches New Tendon Fixation Device System

Stryker’s Trauma & Extremities division has launched its Citrelock Tendon Fixation Device System. The new system provides surgeons a differentiated design via a tendon thread featuring a resorbable technology, known as Citregen, that has unique chemical and...

ACS Advocacy Efforts for Suicide Awareness Underway

Through its Surgeon Well-Being program, the American College of Surgeons (ACS) is working to build awareness about suicide during September, which is National Suicide Awareness and Prevention Month. During September, ACS is releasing several communications for its...

Intermountain Healthcare Postpones Non-Urgent Surgeries and Procedures

Intermountain Healthcare is postponing all non-urgent surgeries and procedures requiring a hospital admission in its trauma and community hospitals, starting September 15, to support ICUs and acute care units and staffing needs.

Encompass Group LLC Awarded Contract with Vizient

Encompass Group LLC has been awarded a contract with Vizient to supply health care apparel uniforms to Vizient members. Effective August 15, 2021, Vizient members can order Encompass Healthcare Apparel directly from Encompass or through their authorized distributor,...

Baxter to Broaden Portfolio of Surgical Products

Baxter International Inc. has announced an agreement to acquire two hemostat and sealant products from Mallinckrodt plc: RECOTHROM Thrombin topical (Recombinant), the first and only stand-alone recombinant thrombin, and PREVELEAK Surgical Sealant, which is used in vascular reconstruction.

“Uncontrolled intraoperative bleeding can lead to a wide variety of clinical and economic complications for patients and hospitals. As a provider of advanced hemostats and sealants, Baxter is focused on continually identifying solutions to help meet surgeons’ varying needs,” said Wil Boren, president of Baxter’s Advanced Surgery business. “We are excited about the addition of RECOTHROM to help surgeons address less severe intraoperative bleeding and PREVELEAK to complement Baxter’s existing portfolio of sealants for cardiovascular and other surgical specialties.”

The transaction is expected to close in the first half of 2018, subject to the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and other customary closing conditions.

Previous

Next

Submit a Comment

Your email address will not be published. Required fields are marked *

X